ionsys
janssen-cilag international nv - fentanil hidroklorid - bolečina, postoperativna - analgetiki - zdravljenje akutne zmerne do hude pooperativne bolečine za uporabo v bolnišničnem okolju.
imipenem/cilastatin teva 500 mg/500 mg prašek za raztopino za infundirane
prašek za raztopino za infundiranje - imipenem in cilastatin
adacel suspenzija za injiciranje
sanofi pasteur - davični toksoid; hemaglutinin, filamentozni; tetanusni toksoid; toksoid b. pertussis; pertaktin; fimbrij tipa 2 in 3 - suspenzija za injiciranje - davični toksoid 2 i.e. / 1 ml hemaglutinin, filamentozni5 i.e. / 1 ml tetanusni toksoid20 i.e. / 1 ml toksoid b. pertussis2,5 i.e. / 1 ml pertaktin3 i.e. / 1 ml fimbrij tipa 2 in 35 i.e. / 1 ml; hemaglutinin, filamentozni 5 i.e. / 1 ml tetanusni toksoid20 i.e. / 1 ml toksoid b. pertussis2,5 i.e. / 1 ml pertaktin3 i.e. / 1 ml fimbrij tipa 2 in 35 i.e. / 1 ml; tetanusni toksoid 20 i.e. / 1 ml toksoid b. pertussis2,5 i.e. / 1 ml pertaktin3 i.e. / 1 ml fimbrij tipa 2 in 35 i.e. / 1 ml; toksoid b. pertussis 2,5 i.e. / 1 ml pertaktin3 i.e. / 1 ml fimbrij tipa 2 in 35 i.e. / 1 ml; pertaktin 3 i.e. / 1 ml fimbrij tipa 2 in 35 i.e. / 1 ml; fimbrij tipa 2 in 3 5 i.e. / 1 ml - cepivo proti oslovskemu kašlju s prečiščenimi antigeni in toksoidi
adacel suspenzija za injiciranje v napolnjeni injekcijski brizgi
sanofi pasteur - davični toksoid; hemaglutinin, filamentozni; tetanusni toksoid; toksoid b. pertussis; pertaktin; fimbrij tipa 2 in 3 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - davični toksoid 2 i.e. / 1 brizga hemaglutinin, filamentozni5 i.e. / 1 brizga tetanusni toksoid20 i.e. / 1 brizga toksoid b. pertussis2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; hemaglutinin, filamentozni 5 i.e. / 1 brizga tetanusni toksoid20 i.e. / 1 brizga toksoid b. pertussis2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; tetanusni toksoid 20 i.e. / 1 brizga toksoid b. pertussis2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; toksoid b. pertussis 2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; pertaktin 3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; fimbrij tipa 2 in 3 5 i.e. / 1 brizga - cepivo proti oslovskemu kašlju s prečiščenimi antigeni in toksoidi
adacel suspenzija za injiciranje v napolnjeni injekcijski brizgi
sanofi pasteur - davični toksoid; hemaglutinin, filamentozni; tetanusni toksoid; toksoid b. pertussis; pertaktin; fimbrij tipa 2 in 3 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - davični toksoid 2 i.e. / 1 brizga hemaglutinin, filamentozni5 i.e. / 1 brizga tetanusni toksoid20 i.e. / 1 brizga toksoid b. pertussis2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; hemaglutinin, filamentozni 5 i.e. / 1 brizga tetanusni toksoid20 i.e. / 1 brizga toksoid b. pertussis2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; tetanusni toksoid 20 i.e. / 1 brizga toksoid b. pertussis2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; toksoid b. pertussis 2,5 i.e. / 1 brizga pertaktin3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; pertaktin 3 i.e. / 1 brizga fimbrij tipa 2 in 35 i.e. / 1 brizga; fimbrij tipa 2 in 3 5 i.e. / 1 brizga - cepivo proti oslovskemu kašlju s prečiščenimi antigeni in toksoidi
refludan
celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antitrombotična sredstva - antikoagulacijo pri odraslih bolnikih s heparinom povzročene trombocitopenije tipa ii in trombemboličnih bolezni, obveznost parenteralne terapije. diagnoza mora biti potrjena z heparina-induced trombocitov aktiviranje testa ali enakovredno test.
porcilis pcv
intervet international bv - prašičji cirkovirus tipa 2 orf2 podenotnega antigena - imunologija za suidae - prašiči - za aktivno imunizacijo prašičev za zmanjšanje obremenitve virusa v krvi in limfnih tkivih in za zmanjšanje izgube teže, povezane z okužbo s prašiči-circovirusom tipa 2, ki se je zgodila med obdobjem pitanja. nastop odpornost: 2 weeksduration imunosti: 22 tednov.
procomvax
sanofi pasteur msd, snc - polyribosylribitol fosfat iz haemophilus influenzae tipa b, kot prp-ompc, zunanja membrana, beljakovine kompleks neisseria meningitidis (zunanje membrane protein complex v b11 sev neisseria meningitidis podskupini b), adsorbira hepatitis b surface antigen, proizvedene v rekombinantne kvasovke celic (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - cepiva - procomvax je indicirano za cepljenje proti invazivni bolezni, ki povzroča haemophilus influenzae tipa b in proti okužbi, zaradi vseh znanih podtipov virusa hepatitisa b pri dojenčkih 6 tednov do 15 mesecev starosti.
prezista
janssen-cilag international nv - darunavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.
efficib
merck sharp and dohme b.v - sitagliptin, metformin hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - za bolnike z tipa 2 sladkorna bolezen:efficib je indicirano kot dodatek k dieti in telesni za izboljšanje glycaemic nadzor pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom sam ali tistih, ki se že zdravijo z kombinacijo sitagliptin in metformin. efficib je navedeno v kombinaciji z sulfonil sečnine (i. trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. efficib je označen kot trojna kombinacija terapije z ppar agonist (i. a thiazolidinedione) kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in ppar agonist. efficib je prikazano tudi kot dodajte na insulin (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor pri bolnikih, pri stabilen odmerek insulina in metforminom sam ne zagotavljajo ustrezne glycaemic nadzor.